Progressive supranuclear palsy and corticobasal degeneration are rare, poorly understood tauopathies with a broad array of symptoms and subtypes. What causes them? How to prevent, diagnose, track, and ...
The latest Pathway grants will fund three projects: "Defining the Role of Microglial Tau in 4R tauopathies" by Dr. Abhirami Kannan Iyer, instructor at Washington University School of Medicine; ...
KYOTO, Japan — The R2 component of the blink reflex recovery cycle (R2 BRRC) appears to be a useful tool to distinguish progressive supranuclear palsy (PSP) from corticobasal degeneration (CBD) with ...
NEW YORK--(BUSINESS WIRE)--Promotus (www.promotus.org) has been launched as a global alliance of non-governmental organizations (NGO’s) focused on providing advocacy, support, and information for ...
NEW YORK, March 30, 2026 /PRNewswire/ -- CurePSP hosted a congressional briefing this month in partnership with Representatives Subramanyam (D-VA) and Bilirakis (R-FL), bringing together lawmakers, ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced an upcoming presentation at Neuro2023 on the design of ORION, a planned ...
Tufted astrocytes? Astrocytic plaques? These tau pathologies mark progressive supranuclear palsy and corticobasal degeneration, respectively. The science of these difficult-to-diagnose diseases may ...
– ORION is a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the safety, efficacy, and tolerability of AMX0035 in adults with PSP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results